



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 12:26
Last Report Issued 02/22/2010 13:51

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2395SP-POS
Patient ID 2395SP-POS
Chain 10000432
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 10000432
Received 02/22/2010 13:50

Sample ID 10000432-001
Matrix Serum or Plasma
Patient Name 2395SP-POS
Patient ID 2395SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

2395SP Iloperidone, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Iloperidone	1.0	ng/mL	0.25	
-------------	-----	-------	------	--

Synonym(s): Fanapt®; Fanapta®; Zomaril®

Peak plasma levels of iloperidone are achieved 2 to 4 hours after ingestion. Steady-state concentrations are attained within 3 to 4 days of dosing. The mean plasma level for iloperidone ranges from 2.2 - 2.7 ng/mL following a single 3 mg dose. In one study that examined the pharmacokinetic and pharmacodynamic relationship in regard to iloperidone efficacy, maximal response in terms of therapeutic benefit was observed at plasma concentrations of 5 - 8 ng/mL. Genetic variations may substantially influence the rate of iloperidone metabolism.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.